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Abstract
Background: A simple diabetes risk tool that does not require laboratory tests would be beneficial in screening individuals
at higher risk. Few studies have evaluated the ability of these tools to identify new cases of pre-diabetes. This study aimed
to assess the ability of the American Diabetes Association Risk Tool (ADART) to predict the 3-year incidence of pre-diabetes
and diabetes in Taiwanese.
Methods: This was a 3-year prospective study of 1021 residents with normoglycemia at baseline, gathered from a random
sample of residents aged 40–88 years in a metropolitan city in Taiwan. The areas under the curve (AUCs) of three models
were compared: ADART only, ADART plus lifestyle behaviors at baseline, and ADART plus lifestyle behaviors and biomarkers
at baseline. The performance of ADART was compared with that of 16 tools that had been reported in the literature.
Results: The AUCs and their 95% confidence intervals (CIs) were 0.60 (0.54–0.66) for men and 0.72 (0.66–0.77) for women in
model 1; 0.62 (0.56–0.68) for men and 0.74 (0.68–0.80) for women in model 2; and 0.64 (0.58–0.71) for men and 0.75 (0.69–
0.80) for women in model 3. The AUCs of these three models were all above 0.7 in women, but not in men. No significant
difference in either women or men (p=0.268 and 0.156, respectively) was observed in the AUC of these three models.
Compared to 16 tools published in the literature, ADART had the second largest AUC in both men and women.
Conclusions: ADART is a good screening tool for predicting the three-year incidence of pre-diabetes and diabetes in
females of a Taiwanese population. The performance of ADART in men was similar to the results with other tools published
in the literature. Its performance was one of the best among the tools reported in the literature.
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Introduction
Diabetes is an important public health problem in the world [1],
even in developing countries [2]. In Lin’s study, using WHO
diagnostic criteria, the prevalence rates of diabetes and impaired
glucose regulation (IGR) were 9.51% (male, 10.08%; female,
9.14%) and 14.40% (male, 14.48%; female, 14.35%) respectively
in Fujian province, southeast China [2]. The prevalence of type 2
diabetes in middle-aged adults in Taiwan increased steadily from
5.1% to 8.2% to 12.8% in 1970, 1986 and 1993, respectively [3,4].
Among men aged 65 years and above, as reflected in the National
Nutrition Survey in Taiwan, the prevalence increased dramatically
from 13.1% to 17.6% to 28.5% in 1993–1996, 2002 and 2005–
2008, respectively [4]. Newly diagnosed diabetes was found in
53.44% of diabetes subjects [3].
Diabetes has become one of the most challenging diseases
threatening the public [5], hence early screening and effective
prevention of diabetes has become a major public health issue. If
we can prevent diabetes in the early stage, then we can take action
against the disease and disability, and reduce complications and
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American Diabetes Association (ADA) lowered the cutoff for IFG
from 110 to 100 mg/dl [6]; it was estimated that the number of
Americans thought to have ‘‘pre-diabetes’’ was 41 million, using
this cutoff point [7].
A simple diabetes risk tool that does not require any laboratory
tests would be beneficial in screening individuals at higher risk.
Previous cross-sectional or longitudinal screening studies have
evaluated the performance of questionnaire-based screening tools
in identifying the prevalence or incidence of diabetes (8–23);
however, few studies have evaluated the ability of those tools to
identify new cases of pre-diabetes.
The ADA has proposed a risk tool for screening diabetes [24],
but its performance for screening pre-diabetes has never been
reported. To remedy this, we have set three aims for this study.
First, we aimed to evaluate the performance of the American
Diabetes Association Risk Tool (ADART) in identifying 3-year
incident cases of pre-diabetes and diabetes in a prospective cohort
study of Taiwanese aged 40–88 years in a metropolitan city in
Taiwan. Second, we compared its performance with that of
ADART plus lifestyle behaviors at baseline, and ADART plus
lifestyle behaviors and biomarkers at baseline in this sample.
Third, we compared the performance of ADART in identifying
the incidence of pre-diabetes and diabetes with that of 16 diabetes
screening tools that had been reported in the literature.
Methods
Study population
This was a longitudinal epidemiological study based on data
from the Taichung Community Health Study (TCHS). At
baseline, a total of 2359 residents of Taichung City in Taiwan,
aged 40 and over, were randomly selected in October 2004 using
multistage sampling [25]. During the period April 2007 to June
2009, the original participants were invited to take part in a follow-
up examination, and 1631 of the 2359 original participants agreed
to participate. Among them, 610 (37%) were excluded from the
analysis because they either had a history of diabetes mellitus or
had evidence of pre-diabetes (FPG $100 mg/dl, according to the
ADA). Therefore, the study population comprised 1021 individ-
uals with normal blood glucose levels. This study was approved by
the Human Research Committee of the China Medical University
Hospital and written informed consent was obtained from each
participant.
Data collection
Anthropometric measurements were obtained during the
complete physical examination. Weight and height were measured
on an auto-anthropometer (super-view, HW-666) while the
subjects were shoeless and wearing light clothing. Body mass
index (BMI) was defined as weight in kilograms divided by height
in meters squared. With the participant standing, waist circum-
ference was measured midway between the superior iliac crest and
the costal margin.
Blood pressure was measured using an electronic device
(COLIN, VP-1000, Japan) three times after the subjects had
rested for 20 minutes. The lowest systolic and diastolic blood
pressure was recorded. Blood was drawn from an antecubital vein
in the morning after a 12-hour overnight fast and was sent for
analysis within four hours of blood collection. Biochemical
markers such as fasting plasma glucose, high-density lipoprotein
cholesterol (HDL-C), triglyceride, urine albumin, and creatinine
were analyzed with a biochemical autoanalyzer (Beckman Coluter
Synchron System, Lx-20, Fullerton, CA, USA) at the Clinical
Laboratory Department of China Medical University Hospital.
The interassay and intraassay CVs for fasting plasma glucose
were 4% and 4%, respectively. We measured cholesterol and
triglyceride in serum mode. Triglyceride levels were determined
by an enzymatic colorimetric method. The HDL-C level was
measured using a direct HDL-C method, and the low-density
lipoprotein cholesterol (LDL-C) level was measured using a direct
LDL-C method.
Data on sociodemographic characteristics, including gender,
smoking, drinking, betel nut chewing, physical activity, time spent
watching TV every week, family history of diabetes, family history
of cardiovascular-related diseases, physician-diagnosed diseases,
and medication history were collected during the complete
physical examination. Information regarding time spent watching
TV was obtained using the open question ‘‘On average, how
many hours a day (or a week) do you spend watching TV?’’
American Diabetes Association Risk Tool
The ADART was constructed according to the 2004 criteria for
screening pre-diabetes [24]. The screening tool comprises eight
self-reported items for both men and women, including age $45
years, BMI $25 kg/m
2, family history of diabetes, race or
ethnicity, level of physical activity, previously identified IFG or
IGT, high blood pressure, HDL cholesterol 35 mg/dl (0.90
mmol/l) and/or triglyceride level $250 mg/dl (2.82 mmol/l), and
history of vascular disease. There are two additional items for
women: history of gestational diabetes mellitus (GDM) or delivery
of a baby weighing .4000 grams (9 lbs), and the presence of
polycystic ovary syndrome. In this study, we did not take race or
ethnicity into account.
Statistical analysis
Baseline characteristics of individuals who were followed up and
those who were not were compared using standardized mean
differences, calculated as the difference in means of a variable
divided by a pooled estimate of the standard deviation of the
variable. This measure is not influenced by sample size and is
useful for comparing cohorts in large observational studies. A
value of 0.1 SD or less indicates a negligible difference in means
between groups [26]. Differences in proportions were assessed
using the Chi-square test. To validate the performance of ADART
combined with different diabetes risk factors, we derived three
logistic regression models: ADART only, ADART plus lifestyle
behaviors at baseline, and ADART plus lifestyle behaviors and
biomarkers at baseline. Those variables which were statistically
significant at a level of 0.25 were brought into the models [27]. A
nonparametric method was used to test whether the areas under
the curve (AUCs) for each receiver operating characteristic curve
of these three models or among different tools were different [28].
Determination of the optimal cutoff points that could be used to
detect pre-diabetes or diabetes was based on the Youden index.
We also calculated the net reclassification improvement (NRI) and
integrated discrimination improvement (IDI) of the models that
included ADART plus lifestyle behaviors at baseline or ADART
plus lifestyle behaviors and biomarkers at baseline compared with
the model with ADART only according to the method of Pencina
et al. [29]. For NRI, four risk categories were chosen a priori: very
low risk (,10%), low risk (10–20%), intermediate (20–30%) and
high risk (.30%).
Results
In general, there were no significant differences in distributions
of sociodemographic variables, anthropometric measurements, or
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followed up and those who were not (Table 1). Of the 1021
participants in this sample, 184 (18%) had elevated FPG levels
(§100 mg/dl) during the three-year follow-up period. Men with
abnormal FPG levels had lower monthly incomes, but had a
higher prevalence of family history of hyperlipidemia, higher
diastolic blood pressure and triglyceride levels than men with
normal levels of FPG. Women with abnormal FPG levels had
lower levels of education but higher weight, larger waist size,
higher BMI, systolic and diastolic blood pressure, triglyceride
levels and higher Framingham scores than women with normal
FPG levels.
Model 1 showed that of the eight self-reported ADART
variables, only a history of cardiovascular disease was associated
with an increased incidence of abnormal FPG in men (OR=2.71,
p,0.01) (Table 2). Model 1 also revealed that the likelihood of
having abnormal FPG levels was higher in women with
BMI 25 kg/m
2 (OR=2.59, p,0.001), HDL ,35 mg/dl or
TG 250 mg/dl (OR=4.27, p,0.001), or gestational diabetes,
or in women who delivered a neonate weighing .4000g
(OR=1.98, p,0.05). In model 2, we further considered family
history and lifestyle behaviors. Men with a family history of
hyperlipidemia were at increased risk of abnormal FPG at a level
of significance of 0.25. Women who had less than 9 years of
education and those who watched TV for greater than or equal to
25 hours per week were at significantly increased risk of abnormal
FPG.
Model 3, which took ADART plus lifestyle behaviors and
biomarkers at baseline into account, revealed that a history of
cardiovascular disease and hypertriglyceride at baseline were
significant variables in the final model in men; in women,
however, there were no additional significant variables.
The areas under the receiver operating characteristic curves
(AUC) for these three multivariate models were similar in men
(AUC=0.60, 95% CI=0.54–0.66 for model 1; AUC=0.62, 95%
CI=0.56–0.68 for model 2; and AUC=0.64, 95% CI=0.58–
0.71 for model 3; p value for overall test: 0.268) (Figure 1A). The
AUC for these three multivariate models were also similar in
women (AUC=0.72, 95% CI=0.66–0.77 for model 1;
AUC=0.74, 95% CI=0.68–0.80 for model 2; and AUC=0.75,
95% CI=0.69–0.80 for model 3; p value for overall test: 0.156)
(Figure 1B); however, they were all above 0.7 and were much
larger than those for men. Using the Youden index to determine
the optimal cutoff points, we found that the sensitivity was 0.77 for
men and 0.76 for women, and that the specificity was 0.35 for men
and 0.54 for women (Table 3). In men, net reclassification
improved by 1.5% when family history of hyperlipidemia was
entered (model 2) and improved by 9.6% when baseline
Table 1. Baseline characteristics in individuals who were followed up and those who were not according to gender.
Men (n=1116) Women (n=1195)
Not followed
n=286
mean (SD)
Followed
n=830
mean (SD)
standardized mean
differences
Not followed
n=394
mean (SD)
Followed
n=801
mean (SD)
standardized
mean
differences
Age (year) 59.29(13.26) 57.78(11.66) 0.007 55.96(11.63) 54.45(9.51) 20.012
Weight (kg) 67.62(10.51) 69.29(10.18) 20.009 58.60(8.97) 57.25(8.36) 20.009
Height (cm) 166.13(6.13) 166.63(6.15) 20.005 154.90(5.39) 155.62(5.29) 20.002
FAT (%) 25.86(5.84) 26.01(5.58) 20.002 37.02(6.19) 35.83(5.88) 20.010
SYS (mmHg) 141.04(21.10) 137.83(20.09) 0.009 136.29(24.63) 130.37(21.15) 20.011
DIA (mmHg) 83.37(12.33) 82.22(11.03) 0.006 77.22(12.85) 74.51(11.93) 20.010
Waist (cm) 85.87(9.01) 86.47(8.65) 20.004 78.14(9.50) 75.97(8.39) 20.007
GOT (IU/L) 28.78(26.04) 27.47(11.88) 0.003 25.93(15.67) 25.64(14.84) 20.036
GPT (IU/L) 30.95(48.61) 29.91(19.26) 0.001 25.56(30.62) 24.62(22.06) 20.071
CHOL (mg/dl) 197.88(39.06) 201.67(35.99) 20.006 205.94(40.27) 206.11(37.48) 20.012
TG (mg/dl) 128.63(97.06) 140.16(117.34) 20.007 112.92(76.73) 104.37(66.66) 20.040
FPG (mg/dl) 110.46(41.05) 104.83(24.74) 0.008 104.91(35.60) 98.96(21.65) 20.020
WBC (10
3/ml) 6.53(1.88) 7.55(38.75) 20.022 5.80(1.64) 5.59(1.47) 20.017
RBC (10
6/ml) 4.94(0.57) 5.00(0.54) 20.006 4.51(0.45) 4.54(0.46) 20.006
HGB (g/dl) 14.82(1.32) 15.05(1.18) 20.010 13.25(1.25) 13.21(1.22) 20.006
HCT (%) 44.27(3.70) 44.86(3.29) 20.009 40.27(3.27) 40.20(3.21) 20.005
PLT (10
3/ml) 227.90(59.52) 224.29(57.10) 0.004 244.73(63.17) 247.67(57.99) 20.015
URIC (mg/dl) 6.37(1.42) 6.30(1.39) 0.003 5.24(1.22) 4.94(1.06) 20.014
HDL (mg/dl) 41.50(10.84) 41.28(10.61) 0.001 49.04(12.36) 50.80(12.78) 20.015
LDL (mg/dl) 126.56(37.00) 128.22(32.77) 20.003 128.39(34.37) 127.13(33.49) 20.016
BUN (mg/dl) 14.50(6.29) 13.87(4.28) 0.006 12.84(4.82) 11.97(3.91) 20.022
MA (mg/g cr) 39.58(209.28) 25.20(100.26) 0.004 28.90(77.33) 20.22(90.65) 20.158
Creatine (mg/dl) 1.11(0.63) 1.05(0.25) 0.006 0.81(0.46) 0.73(0.17) 20.033
SD: standard deviation.
doi:10.1371/journal.pone.0025906.t001
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respectively). The integrated discrimination improved by 0.007
and 0.008 for models 2 and 3, respectively (p=0.1414 and 0.0041,
respectively). In women, net reclassification improved by 0.3%
when education and time for TV watching were entered (model 2)
and improved by 5.0% when baseline diastolic blood pressure was
further entered (model 3) (p=0.1037 and 0.9055, respectively).
The integrated discrimination improved by 0.030 and 0.034 for
models 2 and 3, respectively (p=0.0044 and 0.0028, respectively).
Data on the predictive performance of the 16 screening tools for
pre-diabetes and diabetes in our study are summarized in Table 4.
The largest AUC for pre-diabetes and diabetes in men was 0.64
(95% CI: 0.58–0.70), developed by Schmidt, with 56% sensitivity
and 67% specificity using optimal cutoff values. The AUCs of the
ROC for pre-diabetes and diabetes using the ADA tool were
significantly greater than those for the tools developed by
Ramachandran, Aekplakorn, Lawati, Balkau, Bindraban, but
there was no statistical difference in the AUCs of the ROC
between the ADA tool and the tools developed by Baan, Griffin,
Stern, Lindstro ¨m, Glumer, Mohan, Schulze, de Leo ´n, Cox,
Wilson, and Schmidt. The largest AUC of the ROC for pre-
diabetes and diabetes in women was 0.72 (95% CI: 0.65–0.77),
with 74% sensitivity and 58% specificity. The AUCs for the ADA
tool were significantly greater than for the tools developed by Baan
PM1, Lindstro ¨m, Glumer, Mohan, Romachandran, Lawati,
Schulze, Balkau, Bindraban, and Wilson, but there were no
statistical differences in the AUCs between the ADA tool, and the
tools developed by Baan PM2, Griffin, Stern, Aekplakorn, de
Leo ´n, Cox, and Schimidt for pre-diabetes and diabetes.
None of these tools had a positive likelihood ratio greater than
or equal to 4 in either men or women. On the other hand, three
tools used for males and 10 for females had a negative likelihood
ratio less than or equal to 0.6. These useful tools for men were
developed by Stern, Mohan, and Leon, and for women, were
developed by the ADA, Baan, Griffin, Stern, Schmidt, Lawati,
Schulze, Leon, Balkau, and Cox.
Discussion
In the current study, we evaluated the performance of ADART
in predicting pre-diabetes and diabetes based on questionnaires in
a prospective cohort of Taiwanese. We found that ADART, which
measures self-report variables including age, family history of
diabetes, BMI, physical activity, known history of hypertension,
gestational diabetes history, and obesity, was a valid tool for
predicting the 3-year incidence of pre-diabetes and diabetes, in
ethnic Chinese women.
After taking additional demographic factors, lifestyle behaviors,
physiological factors and biomarkers into account, the differences
in AUCs among these three ROCs were not significant in either
men or women. Especially, when biomarkers were added to the
model with ADART only, there was no improvement in the
prediction of 3-year incidence in both men and women. Because
ADART plus biomarkers at baseline did not improve the
prediction of the three-year incidence of pre-diabetes and diabetes,
compared with ADART only, this may indicate that ADART
alone can be applied to the general population for screening pre-
diabetes and diabetes, or it may indicate that our study did not
Table 2. The ability of ADART plus lifestyle behaviors and biomarkers at baseline for predicting 3-year incidence of pre-diabetes
and diabetes.
OR
Men (n=456) Women (n=565)
model 1 model 2 model 3 model 1 model 2 model 3
ADART
age$45 1.53(0.79, 2.96) 1.57(0.81, 3.04) 1.55(0.79, 3.02) 1.48(0.69, 3.15) 1.17(0.54, 2.52) 1.15(0.53, 2.49)
BMI$25 1.03(0.63, 1.68) 1.06(0.65, 1.73) 1.02(0.62, 1.67) 2.59(1.52, 4.43)*** 2.16(1.25, 3.75)** 2.08(1.19, 3.92)**
family history of diabetes 1.10(0.63, 1.93) 1.00(0.56, 1.77) 0.98(0.55, 1.75) 1.49(0.86, 2.59) 1.60(0.90, 2.82) 1.63(0.92, 2.89)
low physical activity level 1.05(0.64, 1.72) 1.06(0.65, 1.74) 1.04(0.63, 1.71) 0.79(0.45, 1.38) 0.74(0.41, 1.30) 0.74(0.41, 1.31)
previously identified IFG or IGT 1.93(0.33, 11.21) 2.02(0.34, 11.86) 2.05(0.35, 12.18) 2.68(0.18, 40.26) 3.50(0.24, 50.26) 3.06(0.22, 42.77)
high blood pressure 1.37(0.83, 2.27) 1.28(0.77, 2.14) 1.24(0.74, 2.08) 1.17(0.64, 2.11) 1.18(0.65, 2.14) 0.97(0.50, 1.88)
HDL cholesterol#35 or TG$250 (mg/dl) 0.74(0.45, 1.24) 0.74(0.44, 1.25) 0.62(0.36, 1.07) 4.27(2.09, 8.75)*** 4.35(2.10, 9.01)*** 4.46(2.14, 9.32)***
history of cardiovascular disease 2.71(1.36, 5.37)** 2.72(1.37, 5.41)** 2.96(1.47, 5.97)** 0.81(0.28, 2.32) 0.78(0.27, 2.30) 0.79(0.27, 2.35)
history of GDM or delivery of a baby -# -# -# 1.98*(1.04, 3.78) 2.04(1.06, 3.93)* 2.05*(1.06, 3.95)
weighing.4000 g
with polycystic ovary syndrome -# -# -# 1.36(0.50, 3.72) 1.54(0.56, 4.23) 1.64(0.59, 4.52)
family history of hyperlipidemia - 1.87(0.96, 3.65) 1.74(0.89, 3.42) - - -
education attainment#9 years - - - - 1.90*(1.11, 3.25) 1.83*(1.07, 3.14)
TV watching time$25 hrs/week - - - - 1.95*(1.13, 3.37) 1.92*(1.11, 3.33)
baseline triglyceride.150 (mg/dl) - - 1.96*(1.17, 3.28) - - -
baseline diastolic blood pressure$85 mmHg - - - - - 1.65(0.83, 3.27)
*p,0.05;
**p,0.01;
***p,0.001. -#: OR were not available because the items of ADART were only for women; -: OR were not available because the variables did not reach the level of
significance set for entering into models. ADART: American Diabetes Association Risk Tool.
doi:10.1371/journal.pone.0025906.t002
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However, effect sizes calculated by the differences in AUC in men
and women were 0.04 and 0.03, in sensitivity, 0.06 and 0.02, and
in specificity, 0.1 and 0.08, respectively. Given this small
magnitude of increase in effect size, there was limited improve-
ment in screening pre-diabetes and diabetes.
An extensive literature review revealed that there are 16
measures for screening and identifying diabetes addition to
ADART [8–23]. We found that only the tool developed by the
Atherosclerosis Risk in Community (ARIC) Study had a higher
AUC than that of ADART (0.64 vs. 0.60 in men; 0.73 vs. 0.72 in
women), although the difference in the AUC between the two
measures was not significant. The AUC for ADART were
significantly higher than those for the tools developed by
Ramachandran, Aekplakorn, Al-Lawati, Balkau, and Bindraban
[9,18,10,21,22] for men, and by Baan, Lindstro ¨m, Glumer,
Mohan, Romachandran, Al-Lawati, Schulze, Balkau, Bindraban,
and Wilson for women [8–10,14,16,19,20,21,22,23]. The predic-
tive ability of ADART indicates that this tool can be used in
clinical practice to assist in medical decision-making and to
counsel people regarding the likely course of their potential
disease. In particular, early lifestyle intervention and counseling
Figure 1. A—Comparing the AUCs of model 1, model 2, and model 3 in men. B—Comparing the AUCs of model 1, model 2, and model 3 in Women.
doi:10.1371/journal.pone.0025906.g001
Table 3. The predictive performance of American Diabetes Association Risk Tool.
Model AUC (95% CI) p value sensitivity specificity LR
+ LR
- Youdenindex
predicted
probability
# NRI
pv a l u e
for NRI IDI
pv a l u e
for IDI
Male
model 1 0.60 (0.54–0.66) - 0.77 0.35 1.19 0.65 0.12 0.2804 - - - -
model 2 0.62 (0.56–0.68) 0.3171 0.78 0.34 1.19 0.64 0.12 0.3829 0.015 0.9538 0.007 0.1414
model 3 0.64 (0.58–0.71) 0.1055 0.71 0.45 1.28 0.65 0.16 0.2384 0.096 0.7862 0.008 0.0041
Female
model 1 0.72 (0.65–0.77) - 0.76 0.54 1.64 0.44 0.30 0.1181 - - - -
model 2 0.74 (0.68–0.80) 0.2126 0.75 0.60 1.86 0.42 0.35 0.2370 0.003 0.1037 0.030 0.0044
model 3 0.75 (0.69–0.80) 0.0862 0.74 0.62 1.94 0.42 0.36 0.1626 0.050 0.9055 0.034 0.0028
model 1: ADART, model 2: ADART+lifestyle behaviors at baseline, model 3: ADART+lifestyle behaviors+biomarkers; LR
+=positive likelihood ratio test; LR
-=negative
likelihood ratio test; Youden index was defined as the maximum of (sensitivity+specificity-1); #: predicted probability for the optimal cutoff points; NRI: net
reclassification improvement; IDI: integrated discrimination improvement.
doi:10.1371/journal.pone.0025906.t003
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found that the screening program combined with lifestyle
behaviors or blood testing performed slightly better in men than
in women. Although ADART was developed to be used in white
and black populations, this risk assessment tool performed well in
this Taiwanese population.
This is the first study to prospectively validate a tool for risk
assessment of pre-diabetes and diabetes. Although we used a
standardized data collection procedure and evaluated a large
number of behavioral factors, we did not perform oral glucose
tolerance testing or measure the 2-h glucose concentration. In
addition, some of the variables measured with other tools, such as
Table 4. ADART and instruments published in literature in screening undiagnosed pre-diabetes and diabetes.
Tools AUC (95%CI) sensitivity specificity LR+ LR- Youden index
Men
ADA
24 0.60(0.54–0.66) 0.24 0.90 2.47 0.84 0.14
Baan
14
PM1 0.57(0.51–0.63) 0.77 0.35 1.18 0.66 0.12
PM2 0.54(0.48–0.60) 0.90 0.18 1.10 0.54 0.08
Griffin
a, 12 0.54(0.47–0.60) 0.69 0.38 1.11 0.82 0.07
Stern
b, 15 0.60(0.54–0.66) 0.72 0.45 1.30 0.63 0.17
Lindstro ¨m
16 0.55(0.48–0.61) 0.86 0.23 1.12 0.61 0.09
Glu ¨mer
23 0.56(0.50–0.62) 0.55 0.58 1.30 0.78 0.13
Mohan
8 0.53(0.47–0.59) 0.96 0.10 1.07 0.39 0.06
Ramachandran
9 0.51(0.44–0.57)* 0.27 0.79 1.28 0.92 0.06
Schmidt
b, 17 0.64(0.58–0.70) 0.56 0.67 1.71 0.65 0.23
Aekplakorn
18 0.50(0.44–0.57)* 0.27 0.77 1.19 0.94 0.04
Lawati
10 0.52(0.46–0.58)* 0.18 0.87 1.35 0.95 0.05
Schulze
c, 19 0.55(0.49–0.61) 0.73 0.40 1.22 0.67 0.13
Leo ´n
11 0.57(0.51–0.63) 0.74 0.44 1.32 0.59 0.18
Wilson
20 0.54(0.48–0.60) 0.71 0.38 1.14 0.77 0.09
Balkau
22 0.50(0.44–0.56)* 0.82 0.21 1.03 0.87 0.03
Bindraban
21 0.53(0.47–0.59)* 0.71 0.35 1.09 0.84 0.06
Cox
13 0.52(0.46–0.59) 0.09 0.95 1.83 0.96 0.04
Women
ADA
24 0.72(0.65–0.77) 0.74 0.58 1.76 0.45 0.32
Baan
14
PM1 0.58(0.52–0.64)* 0.35 0.76 1.47 0.86 0.11
PM2 0.69(0.64–0.75) 0.80 0.52 1.65 0.39 0.31
Griffin
a, 12 0.66(0.60–0.72) 0.74 0.52 1.55 0.50 0.26
Stern
b, 15 0.73(0.67–0.79) 0.71 0.65 2.02 0.44 0.36
Lindstro ¨m
16 0.62(0.55–0.69)* 0.30 0.87 2.28 0.81 0.17
Glumer
23 0.62(0.56–0.69)* 0.54 0.67 1.60 0.70 0.20
Mohan
8 0.53(0.46–0.60)* 0.14 0.91 1.55 0.94 0.05
Ramachandran
9 0.64(0.58–0.71)* 0.63 0.58 1.52 0.63 0.21
Schmidt
b, 17 0.73(0.67–0.79) 0.83 0.55 1.84 0.30 0.38
Aekplakorn
18 0.68(0.62–0.74) 0.54 0.70 1.76 0.67 0.23
Lawati
10 0.63(0.57–0.69)* 0.85 0.39 1.40 0.39 0.24
Schulze
c, 19 0.65(0.59–0.71)* 0.73 0.54 1.58 0.51 0.27
Leo ´n
11 0.65(0.59–0.71) 0.85 0.39 1.39 0.40 0.24
Wilson
20 0.63(0.56–0.70)* 0.54 0.66 1.57 0.70 0.20
Balkau
22 0.65(0.59–0.71)* 0.67 0.57 1.55 0.59 0.24
Bindraban
21 0.65(0.59–0.71)* 0.48 0.74 1.83 0.71 0.22
Cox
13 0.67(0.61–0.73) 0.90 0.35 1.39 0.27 0.25
a: The current study did not consider the item ‘‘prescribed steroid’’ that was in the original screening tool;
b: The current study did not consider the item ‘‘ethnic’’ that was in the original screening tool;
c: The current study did not consider the items ‘‘ intake of red meat’’ and ‘‘ intake of whole-grain’’ that were in the original screening tool;
*p,0.05 for comparing the AUC of the specific screening tool with that of ADA.
doi:10.1371/journal.pone.0025906.t004
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whole grain in Schulze’s study, were not included when we
compared the predictive ability of ADART with that of the other
tools.
In conclusion, we found that the use of ADART alone in
community screening predicts the 3-year incidence of pre-diabetes
and diabetes well in females. Its performance was one of the best
among the tools reported in the literature. This was the first testing
of this simple screening tool in the Taiwanese population.
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